corticotropin-releasing factor

Human CRF acetate is a chemical compound that effectively stimulates the synthesis and secretion of adrenocorticotropin in the anterior pituitary.

Corticotropin-releasing factor human (Human CRF; Human corticotropin-releasing factor) is an immunomodulatory neuropeptide that releases ACTH from the anterior pituitary, stimulates the sympathetic nervous system and adrenal medulla, reduces hyperpolarizations, and acts as a functional antagonist of inflammatory mediators.

Corticotropin-releasing factor (human) acetate stimulates to synthesize and secret adrenocorticotropin in the anterior pituitary.

CP 376395 (CP-316311) is an effective and specific Corticotropin-releasing factor 1 (CRF1) receptor antagonist.

Verucerfont (NBI77860) is an antagonist of corticotropin-releasing factor receptor 1 (CRF1) .

α-Helical Corticotropin Releasing Factor (9-41) is a corticotropin releasing factor (CRF) antagonist that reduces plasma growth hormone (GH) levels in vivo [1] [2].

α-Helical Corticotropin Releasing Factor (12-41), a 30-amino-acid α-helical analogue of corticotropin releasing factor/hormone (CRF), is a hypothalamic hormone that promotes adrenocorticotrophic hormone (ACTH) secretion. This compound counteracts CRF's stimulatory effect on ACTH secretion [1] [2].

[DPro5] Corticotropin Releasing Factor, human, rat, a selective R2 agonist of corticotropin-releasing factor/hormone (CRF), is a hypothalamic hormone that prompts the release of adrenocorticotropic hormone (ACTH) and β-endorphin. Unlike typical agents, it does not induce anxiogenic effects but instead influences learning and memory processes in rats [1].

Corticotropin Releasing Factor, ovine [Met(O)21], is a hypothalamic hormone isolated from ovine hypothalamic extracts. It functions by stimulating the secretion of adrenocorticotrophic hormone (ACTH) [1].

[Tyr^0] Corticotropin Releasing Factor, ovine, is a hypothalamic hormone sourced from sheep that prompts the secretion of adrenocorticotropic hormone (ACTH) and β-endorphin [1] [2].

α-Helical CRF (9-41) is a synthetic peptide antagonist that targets corticotropin-releasing factor (CRF), effectively inhibiting CRF-induced adrenocorticotropic hormone (ACTH) release both in vitro, with isolated rat anterior pituitary cells at concentrations of 0.5 to 5 µM, and in vivo, in non-anesthetized, intact rats at doses ranging from 0.02 to 0.6 µmol/kg. Moreover, it prevents stress-induced ACTH release at a dose of 0.6 µmol/kg in rats and demonstrates the ability to enhance social interaction times in a rat model addressing nicotine-induced conditioned anxiety, in addition to decreasing binge-like ethanol consumption in mice.

Urocortin, human (Human urocortin I) is a 40 amino acid peptide which is closely related to corticotrophin-releasing factor (CRF).

CRF, bovine (TFA) is a potent agonist of CRF receptor, and displaces [125I-Tyr]ovine CRF with a Ki of 3.52 nM.CRF, bovine is a potent agonist of CRF receptor, and displaces [125I-Tyr]ovine CRF with a Ki of 3.52 nM[1]. CRF shows pEC50s of 11.16, 8.53 and 8

CRF, bovine, is a potent agonist of the CRF receptor and displaces [125I-Tyr]ovine CRF with a Ki of 3.52 nM.

Crinecerfont (SSR-125543) is a selective antagonist of corticotropin-releasing factor 1 receptor (CRF1) and can be used in studies about Classic congenital adrenal hyperplasia.

Pivagabine (CXB-722), a hydrophobic 4-aminobutyric acid derivative, exhibits neuromodulatory activity and successfully penetrates the blood-brain barrier in rats. It counteracts the impact of foot shock on GABAA receptor function and corticotropin-releasing factor (CRF) levels in the rat brain.

NVS-CRF38 is an antagonist of corticotropin-releasing factor receptor 1 (CRF1).

Emicerfont is an antagonist of the corticotropin-releasing factor type 1 receptor (IC50: 66 nM).

Pexacerfont (BMS-562086) is a selective antagonist of the corticotropin-releasing factor receptor (IC50: 6.1±0.6 nM for the human CRF1 receptor).

Vasopressin-D5 trifluoroacetate is the trifluoroacetic acid salt form of Vasopressin-D5, an isotopically labeled derivative of Vasopressin. Vasopressin, a cyclic nonapeptide, is synthesized in the medial hypothalamus and plays a critical role in the hypothalamic-pituitary-adrenal axis by enhancing the stimulation of corticotropin-releasing factor, thereby regulating the secretion of adrenocorticotropic hormone. Additionally, Vasopressin acts as a neurotransmitter, exerting its effects through interaction with specific G-protein-coupled receptors.

AAG561 is a corticotropin-releasing factor receptor 1 (CRF1) antagonist. It is useful for researching potential emotional dysregulation associated with psychiatric disorders or mental illnesses.

Antalarmin hydrochloride is an antagonist of corticotropin-releasing factor 1(CRF1). Antalarmin hydrochloride produces anti-inflammatory effects and suppresses stress-induced gastric ulceration related to irritable bowel syndrome.

CP 154526 hydrochloride is a blood-brain barrier-penetrant, selective CRF1 (corticotropin-releasing factor receptor 1) antagonist (Ki = 2.7 nM) exhibiting thousands of times greater selectivity for CRF1 over CRF2, with anxiolytic and antidepressant activities.

corticotropin-releasing factor receptor 1 (CRF1) antagonist